Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Nuvalent, Inc.
NUVL
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.1B
$123.69
▲ +0.07%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$71.13 - $123.74
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 53.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Brain-penetrant drug design addressing CNS metastases and treatment resistance
- Focused pipeline targeting high-value oncology indications with limited treatment options
- Intellectual property protecting next-generation kinase inhibitor technology
- Experienced management team with deep oncology and drug development expertise
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Clinical trial progression and positive efficacy/safety data for NVL-520 and NVL-655
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+17.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NUVL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 7, 2026
Reported EPS of -$1.39 vs -$1.35 consensus (-3.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-3.0%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
8 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
$177.00
▲ +43.1% vs $123.69
Latest: Bernstein · Jun 24, 2026
2 analysts covering